Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients

Condition:   Non-Germline BRCA Mutated Ovarian Cancer Intervention:   Drug: Olaparib Sponsors:   AstraZeneca;   Quintiles, Inc.;   Myriad Genetics, Inc.;   Covance;   Theradex;   Parexel Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials